These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32525730)

  • 1. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
    Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
    J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
    Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
    Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Sep; 22(5):749-765. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
    Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
    Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
    Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    Schultz LM; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Rouce RH; Chinnabhandar V; Kunicki M; Barsan VV; Goksenin AY; Li Y; Mavroukakis S; Egeler E; Curran KJ; Mackall CL; Laetsch TW
    J Clin Oncol; 2022 Mar; 40(9):945-955. PubMed ID: 34882493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
    Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
    Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
    J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
    N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
    Levine JE; Grupp SA; Pulsipher MA; Dietz AC; Rives S; Myers GD; August KJ; Verneris MR; Buechner J; Laetsch TW; Bittencourt H; Baruchel A; Boyer MW; De Moerloose B; Qayed M; Davies SM; Phillips CL; Driscoll TA; Bader P; Schlis K; Wood PA; Mody R; Yi L; Leung M; Eldjerou LK; June CH; Maude SL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34353848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of gilteritinib for relapsed/refractory
    Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.